麦谷物多基提取物在细胞检测中展示了与阿尔茨海默病相关的神经保护作用
Nasim Rezaee1, Eugene Hone1, Hamid R Sohrabi1,2,3
1Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.
Foods (Basel, Switzerland)
|June 19, 2024
概括
多显示神经保护作用对阿尔茨海默病 (AD) 通过减少粉样β聚合和氧化应激. 这些发现突出显示了.
科学领域:
- 营养神经科学 营养神经科学
- 生物化学 生物化学
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默氏病 (AD) 的发病包括氧化压力,粉样β (Aβ) 聚合,神经毒性和线粒体功能障碍.
- 来自谷的多 (PPs) 具有抗氧化特性,对AD有潜在的治疗应用.
- PPs可能会抵消与AD相关的细胞损伤.
研究的目的:
- 量化六种的化合物和抗氧化能力.
- 研究PP提取物对人类神经母细胞瘤细胞对Aβ和tau诱导的毒性,Aβ聚合,线粒体功能障碍和活性氧物种 (ROS) 的神经保护作用.
主要方法:
- 使用化学分析量化PP和抗氧化能力.
- 通过MTS测定评估Aβ和tau诱导的毒性.
- 使用 thioflavin T (Th-T) 试验对抗Aβ聚合的评估.
- 使用DCFDA和MitoSOX测定分别测量ROS和线粒体超氧化物.
主要成果:
- 糖果品种Shawaya short black-1和IS1311C的总,黄和抗氧化能力最高.
- 所有的糖果提取物显著提高了细胞活力,并减少了Aβ聚合.
- 品种QL33表现出对Aβ毒性的最强的保护作用 (28%的细胞死亡减少).
- 大多数提取物显著降低了Aβ-和三甲基丁氧化物 (TBHP) 诱导的ROS和线粒体超氧化物,以剂量和品种依赖的方式.
结论:
- 的多基提取物对与AD相关的细胞损伤具有显著的神经保护作用.
- 这些发现表明,基食品可能为AD预防或管理提供饮食益处.
- 需要进一步的体内和体外研究来验证这些有希望的神经保护性质.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.粉样化物-β-β 的存在.抗氧化剂 抗氧化剂是一种抗氧化剂.线粒体功能 线粒体功能神经保护神经保护聚醇是一种多醇.有活性氧物种的反应性氧物种.这就是. sorghum.更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
06:14Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
Published on: May 8, 2018
8.8K
相关概念视频
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
